June 22, 2017. We agree with the USPSTF’s assessment that there is inadequate evidence to support screening for adolescent idiopathic scoliosis. However, we are concerned that the change of grade from a “D” to “I” will be interpreted as if there is now more evidence to support screening instead of less confidence in the data surrounding its use.
Read More »On Health Policy
Letter to Secretary Perdue of USDA Concerning Antimicrobial Resistance
June 21 2017: In a letter signed by 34 health and consumer groups to the USDA, we asked for stronger action against antibiotic resistance by improving tracking, using fewer antibiotics on farms, and supporting research to keep people safe.
Read More »Letter to Secretary Price of HHS Concerning Antimicrobial Resistance
June 21 2017: In a letter signed by 34 health and consumer groups to the HHS, we asked for stronger action against antibiotic resistance by improving tracking, using fewer antibiotics on farms, and supporting research to keep people safe.
Read More »NCHR Remarks to the FDA Science Board on Patient Engagement
The National Center for Health Research tells the FDA it’s important to hear from real patients, not just those backed by drug companies, so that decisions about new medicines and treatments are safer and more fair.
Read More »Letter Opposing Amendments to FDA’s User Fee Program that Weaken Patient Safeguards
June 5, 2017. When an unproven assertion of safety and effectiveness is relied on to market a medical product, the resulting harm may be severe—even life-threatening.
Read More »